Publix Sales Growth Slows Down

Publix’s sales growth continues to slow, marking the fourth consecutive quarter of deceleration for the Florida-based grocer. The company announced Monday that revenue rose 1% to $15.7 billion during its second quarter, which ended June 27, while comparable-store sales slipped 0.5%.

The results show a sharp contrast to the previous year. Sales and comparable-store sales both jumped 7.3% and 6%, respectively, during the second quarter of fiscal 2025. The decline marks the fourth straight period where growth has moderated, with comp-store sales turning negative for the first time in recent memory.

The grocer’s net earnings for the quarter hit $1.7 billion, a figure that is up more than 20% compared to the same period last year. Investors appear focused on profitability despite the sales headwinds. The slowdown is largely attributed to reduced drug prices tied to the federal Inflation Reduction Act and a shift in consumer spending habits.

Impact of Drug Pricing

Publix joins a growing list of retailers, including Albertsons and Walmart, feeling the pinch from the Inflation Reduction Act. Under the law, which went into effect at the start of this year, prices for 10 major drugs were lowered. This includes popular medications like Jardiance and Farxiga for diabetes, as well as the blood thinner Eliquis.

Related: Lidl US launches employee discount program

For grocers that historically relied on pharmacy margins to boost overall revenue, these reimbursement changes have hit hard. The lowered prices for these treatments have directly reduced pharmacy income at stores across the Southeast. Publix stated that these reimbursement changes partially offset new supermarket sales, resulting in the modest 1% overall growth figure.

The grocer also cited “economic conditions impacting consumer spending” as a factor contributing to the sales decline. Despite the challenges, the company continues to expand its physical footprint. During the six months ended June 27, Publix opened 16 new stores, remodeled 56 locations, and closed eight. The company runs approximately 1,440 supermarkets throughout the region.

Management has attempted to counter the pressure on pharmacy revenue by joining the Medicare GLP-1 Bridge program. This temporary federal initiative allows eligible Medicare customers to obtain select GLP-1 prescriptions for a flat rate of $50 per month at Publix pharmacies. While this move aims to stabilize prescription volumes, the broader impact of the Inflation Reduction Act on retail pharmacy margins remains a significant hurdle for the company’s future growth trajectory.

Similar cost-saving measures are being implemented by other major retailers. Lidl US has recently launched an employee discount program to support its workforce. This initiative mirrors broader trends in the retail sector where companies seek to balance operational costs with employee retention strategies.